about
TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomasGenetic alterations in poorly differentiated and undifferentiated thyroid carcinomasHow to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid CancerThe biology and the genetics of Hurthle cell tumors of the thyroid.Osteopontin expression is correlated with differentiation and good prognosis in medullary thyroid carcinoma.Frequency of TERT promoter mutations in human cancers.Chromosomal, epigenetic and microRNA-mediated inactivation of LRP1B, a modulator of the extracellular environment of thyroid cancer cells.Genetic imbalances detected by multiplex ligation-dependent probe amplification in a cohort of patients with oral squamous cell carcinoma-the first step towards clinical personalized medicine.Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.Estrogen receptor, progesterone receptor, and bcl-2 are markers with prognostic significance in CIN III.Genetic gains and losses in oral squamous cell carcinoma: impact on clinical management.Characterization of HPV genotype profile in squamous cervical lesions in Portugal, a southern European population at high risk of cervical cancer.WT1, MSH6, GATA5 and PAX5 as epigenetic oral squamous cell carcinoma biomarkers - a short report.mTOR activation in medullary thyroid carcinoma with RAS mutation.A Polymorphism in the Promoter Region of the Selenoprotein S Gene (SEPS1) Contributes to Hashimoto's Thyroiditis SusceptibilityLoss of heterozygosity at 19p13.2 and 2q21 in tumours from familial clusters of non-medullary thyroid carcinomaLiposomal therapies in oncology: does one size fit all?
P50
Q34313648-EA4D11E7-320D-4004-9860-5C6543260D35Q35731037-A55E8CED-1BB5-42D0-A731-8DD65692EE42Q37902072-3A2C87C2-51E8-43D8-9593-226BCAA15570Q38003587-B0EE35EF-92C6-4E8E-ACCF-C03A1B6C8F60Q38799394-1F2EC1B5-CB2F-4BC7-922C-864A2B29BB6CQ39120274-DAA8F336-CBA6-4CE1-853C-C10F24BF1C06Q39634789-97631750-239D-48F6-B827-FC6BAFF8E6D4Q42240179-A2531064-5782-49A1-A60D-C2F2621D8E81Q42686258-B0ECFC9F-AA9A-4067-B318-52D297B7AD5BQ42811031-EEB3B89C-0391-4702-95FE-0F81AB707C21Q44107488-F27BE79C-9568-47C2-97C9-13919CE74049Q51855317-8F90A94F-CF7F-47A0-B1A5-15F0562F3888Q52805721-9E6F98FA-E25A-4D3C-8E62-4A245E4EAF22Q54638455-97BA4ECD-6063-4A87-B58A-87FF951908A6Q55071575-3ECD9E28-29BC-49C0-AABE-64C4338B3E14Q57558985-2FF96FED-773F-4BDC-9732-FAD38189D960Q58876485-46859686-1C86-4152-A0B1-9721EAE1F45CQ58923767-9D88E898-1ADA-4096-BB49-02D317AA81AF
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Hugo Prazeres
@ast
Hugo Prazeres
@en
Hugo Prazeres
@es
Hugo Prazeres
@nl
Hugo Prazeres
@pt
Hugo Prazeres
@sl
type
label
Hugo Prazeres
@ast
Hugo Prazeres
@en
Hugo Prazeres
@es
Hugo Prazeres
@nl
Hugo Prazeres
@pt
Hugo Prazeres
@sl
altLabel
Prazeres HJ
@en
prefLabel
Hugo Prazeres
@ast
Hugo Prazeres
@en
Hugo Prazeres
@es
Hugo Prazeres
@nl
Hugo Prazeres
@pt
Hugo Prazeres
@sl
P106
P1153
8846912900
P21
P31
P496
0000-0002-5504-6642